Aquestive Resubmits Anaphylm NDA After Addressing FDA Deficiencies; Bear Case Strengthens

What happened

On September 17, 2026, Aquestive Therapeutics announced resubmission of its NDA for Anaphylm to the FDA, following positive topline human factors and pharmacokinetic study results from August 2026. The resubmission indicates the FDA's initial review, originally due January 31, 2026, resulted in deficiencies that required additional data, confirming the bear scenario outlined in our prior report that regulatory hurdles would delay approval. The company has now addressed human factors and PK concerns, but the FDA will determine resubmission classification and review timeline, adding further uncertainty about when, and if, approval will occur. The delay extends Aquestive's cash burn without revenue contribution from Anaphylm, compounding pressure on its already encumbered balance sheet and leveraged capital structure. While a resubmission is a necessary step, it does not eliminate the risk of additional FDA requests or a second CRL, and competitive pressures from neffy and generic auto-injectors continue to intensify during the delay.

Implication

Investors should treat this resubmission as a negative signaling event that increases the probability of prolonged regulatory uncertainty and further delays to Anaphylm commercialization. The need for additional human factors and PK studies suggests the FDA had substantive concerns about real-world usability and dosing reliability, which may not be fully resolved by the new data alone. Even if the resubmission leads to approval, the extended timeline means Aquestive will face a more entrenched neffy and generic epinephrine market with payer contracts already locked in, likely requiring deeper discounts and higher launch costs. The company's cash position, reported at $129.1 million as of Q3 2025, will have deteriorated further by mid-2026, and the balance sheet remains burdened by 13.5% notes and royalty obligations, increasing dilution risk if additional capital is needed. Given these dynamics, the previous 'POTENTIAL SELL' rating remains appropriate, and the attractive entry of $4.50 now appears too optimistic; the bear scenario implied value of $3.50 becomes more relevant as base case probability shifts upward.

Thesis delta

The original thesis assigned 40% probability to a bear scenario where FDA requires additional studies or imposes constraints, and this resubmission confirms that outcome. The probability of the bear scenario should now be increased to at least 60%, reflecting the demonstrated regulatory friction and further delay. Consequently, the base case implied value of $7.00 is less achievable, and the stock's fair value skews toward the bear case $3.50, reinforcing the 'POTENTIAL SELL' rating.